Company Profile
Vaxcyte Stock Price, News & Analysis
- Ticker:
- PCVX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
58.89 USD (+5.31%)
Close
Last updated: August 6, 2026
6.85B USD
Market cap
Why the stock is moving
Following the latest company update, “Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update”, PCVX closed up 5.31% at $58.89 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Carrier-Sparing Vaccine Platform
Vaxcyte develops broad-spectrum conjugate vaccines using a platform designed to include more bacterial antigens without overloading the carrier proteins needed to generate immune responses.
Adult VAX-31 Program
VAX-31 is a 31-valent pneumococcal conjugate vaccine in Phase 3 development for adults. The OPUS program compares its immune responses with currently available pneumococcal vaccines and evaluates coadministration and safety.
Infant VAX-31 Program
A Phase 2 dose-finding study is evaluating VAX-31 as part of the primary infant immunization series and a booster dose.
VAX-A1
VAX-A1 is a preclinical vaccine designed to protect against disease caused by Group A *Streptococcus* and is preparing for initial testing in adults.
Manufacturing Infrastructure
Vaxcyte and Lonza have completed construction of dedicated large-scale manufacturing capacity intended to support future global supply of the company's pneumococcal vaccines.
Future catalysts
Initiation of a Phase 1 adult study of VAX-A1 around mid-2026.
Topline Phase 3 OPUS-1 data for VAX-31 in the fourth quarter of 2026.
Phase 3 OPUS-2 and OPUS-3 results in the first half of 2027.
Infant Phase 2 primary-series and booster data by the end of the first half of 2027.
Recent news
- 01
- 02
Vaxcyte to Participate in Upcoming Investor Conferences
Source: Vaxcyte
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Vaxcyte (PCVX)?
Vaxcyte (PCVX) most recently closed at 58.89 USD, a +5.31% move versus the previous session.
What is the market cap of Vaxcyte (PCVX)?
Vaxcyte currently has a market capitalization of 6.85B USD on BioPharmSignal.
What does Vaxcyte do?
Carrier-Sparing Vaccine Platform Vaxcyte develops broad-spectrum conjugate vaccines using a platform designed to include more bacterial antigens without overloading the carrier proteins needed to generate immune responses. Adult VAX-31 Program VAX-31 is a 31-valent pneumococcal conjugate vaccine in Phase 3 development for adults. The OPUS program compares...
On which exchange is PCVX stock listed?
Vaxcyte (PCVX) is associated with NASDAQ, United States, Biopharma.
What is VAX-31?
Topline Phase 3 OPUS-1 data for VAX-31 in the fourth quarter of 2026.
Which conditions is Vaxcyte targeting with VAX-31?
Topline Phase 3 OPUS-1 data for VAX-31 in the fourth quarter of 2026.
How does Vaxcyte describe recent progress with VAX-31?
Topline Phase 3 OPUS-1 data for VAX-31 in the fourth quarter of 2026.
What is VAX-A1?
VAX-A1 VAX-A1 is a preclinical vaccine designed to protect against disease caused by Group A *Streptococcus* and is preparing for initial testing in adults.